Gilead Sciences will pay up to $90 million over three years to Verily to run a suite of tests on the white blood cells of patients with rheumatoid arthritis, inflammatory bowel disease, and lupus in the hopes of identifying which patients respond to existing drugs.
You could do far worse than read the recently published "Walk A Mile: Tales of a Wandering Loon." It’s about a regular working man who battles his illness and largely wins.